Dec 29, 2025 04:07PM Clear Street Starts Palisade Bio Inc. (PALI) at Buy

Dec 29, 2025 03:39AM Piper Sandler Starts Palisade Bio Inc. (PALI) at Overweight

Dec 2, 2025 08:45AM Palisade Bio appoints James Izanec as VP of clinical development

Oct 13, 2025 08:46AM Palisade Bio receives Canadian patent for PALI-2108 drug composition

Sep 29, 2025 06:47AM Palisade Bio files to offer 147 million shares of common stock

Sep 26, 2025 04:05PM Palisade Bio adjourns stockholder meeting due to lack of quorum

Aug 15, 2025 04:09PM Palisade Bio Inc. (PALI) Files for 8.9M Share Offering by Selling Stockholders

Jul 22, 2025 08:40AM JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live

Jul 9, 2025 08:45AM Palisade Bio names Emil Chuang to board of directors

May 27, 2025 08:33AM Palisade Bio Inc. (PALI) reports positive Phase 1a results for PALI-2108 trial

May 6, 2025 08:32AM Palisade Bio (PALI) Presents Positive Preclinical Data Highlighting Potential of PALI-2108

Apr 9, 2025 08:31AM Palisade Bio Inc. (PALI) Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Mar 12, 2025 08:32AM Palisade Bio Inc. (PALI) Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation

Feb 20, 2025 08:46AM Palisade Bio (PALI) Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis

Feb 10, 2025 08:45AM Palisade Bio Inc. (PALI) Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Jan 16, 2025 08:03AM Palisade Bio Inc. (PALI) Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis

Dec 17, 2024 08:34AM Palisade Bio Inc. (PALI) Appoints Brian Feagan to its Board

Dec 12, 2024 12:08PM Palisade Bio (PALI) Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Nov 12, 2024 04:48PM Palisade Bio Inc. (PALI) Misses Q3 EPS by 232c

Nov 7, 2024 08:31AM Palisade Bio Inc. (PALI) Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis

Oct 31, 2024 08:33AM Palisade Bio (PALI) Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Oct 30, 2024 06:10AM Palisade Bio Inc. (PALI) Files for Share and Warrant Offering

Oct 10, 2024 08:32AM Palisade Bio (PALI) Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

Sep 25, 2024 08:01AM Palisade Bio Inc. (PALI) Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

Sep 5, 2024 08:01AM Palisade Bio Inc. (PALI) Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification

Aug 13, 2024 10:35AM Palisade Bio Inc. (PALI) Misses Q2 EPS by 332c

Aug 8, 2024 08:00AM Palisade Bio (PALI) Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

Jul 29, 2024 09:08AM Palisade Bio (PALI) Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

Jul 19, 2024 08:32AM Palisade Bio Inc. (PALI) Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

Jul 11, 2024 08:05AM Palisade Bio (PALI) Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Jun 21, 2024 08:15AM Palisade Bio Inc. (PALI) Provides Update on Collaboration with Strand Life Sciences

Jun 11, 2024 08:34AM Palisade Bio (PALI) Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108